This invention provides isolated 
nucleic acid molecules encoding a mammalian 
glycine transporter, isolated 
nucleic acid molecules encoding a human 
glycine transporter, isolated proteins which are mammalian 
glycine transporter proteins, isolated proteins which are human 
glycine transporter proteins, vectors comprising isolated 
nucleic acid molecules encoding a mammalian or a human 
glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian 
glycine transporter, antibodies directed to a human glycine transporter, 
nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, 
nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, 
antisense oligonucleotides complementary to any sequences of a 
nucleic acid molecule which encodes a mammalian glycine transporter, 
antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds related to mammalian glycine transporter and nonhuman transporter, pharmaceutical compounds related to human glycine transporter and nonhuman transgenic animals which express 
DNA encoding a normal or a 
mutant mammalian or human glycine transorter. This invention also provides methods for determining ligand binding, detecting expression, 
drug screening, and treatments for alleviating abnormalities associated with mammalian glycine transporter. This invention further provides methods for determining ligand binding, detecting expression, 
drug screening, and treatments for alleviating abnormalities associated with human glycine transporter.